FDA Panel: Philip Morris Data Do Not Support Reduced Disease Risk Claims On IQOS

An FDA expert panel rejected Philip Morris International’s claim that its smokeless tobacco product, IQOS, could reduce users’ risk of tobacco-related disease, but the experts did approve of the company's claim that the product would reduce a user's exposure to harmful chemicals. The experts were also hesitant to believe that consumers would accurately understand the risks of IQOS as communicated through the company’s proposed labeling. Multiple committee members expressed concern over lack of data underlying some of the questions they...